Skip to main content
Premium Trial:

Request an Annual Quote

Celera, SomaLogic Pen Multi-Year Proteomics Deal

NEW YORK, Aug 16. – Proteomics company SomaLogic said Thursday it had signed a multi-year deal to provide Celera with early access to its aptamers and aptamer arrays.

In exchange, SomaLogic will receive access to Celera’s sequence data and proteins with which it can develop additional aptamers.

Aptamers are DNA or RNA molecules that have been artificially manipulated to bind with molecules and viruses. They are considered to have many potential uses in medicine and diagnostics.

SomaLogic's aptamer technology uses nucleic acids to bind to distinct proteins. Assembled in an array format, the company said its approach is designed to allow researchers to detect thousands of proteins and link them with particular diseases.

"SomaLogic's aptamer technology complements our genomics and proteomics programs by providing a unique approach for identifying expression and function of multiple proteins likely to play a role in major disease," Craig Venter, Celera's president and chief scientific officer, said in a statement. 

"This agreement should strengthen our proteomics capability and helps our expansion in drug discovery," he added. 

SomaLogic, of Boulder, Colo., was established in 1999. The company is also using its aptamer research to develop diagnostic tools. 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.